Login to Your Account



A Look at Lupus

Human Genome's Benlysta: First of Many or a Fluke?

By Brian Orelli


Monday, March 14, 2011
After a 56-year dearth, the FDA has finally signed off on a new medication for lupus. Last week, the agency approved Human Genome Sciences Inc.'s and partner GlaxoSmithKline plc's Benlysta (belimumab) for treating systemic lupus erythematosus (SLE). (See Bioworld Today, Mar. 11, 2011.)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription